Blog
CARLSBAD, Calif., Aug. 17, 2023 (GLOBE NEWSWIRE) Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, announced today it is partnering with Translational Drug Development (TD2) as the contract research organization (CRO) to conduct the Phase 1 clinical...
SCOTTSDALE, ARIZONA, UNITED STATES, May 17, 2023 / EINPresswire.com/ — Titan CEO and headline sponsor Wipfli LLP are pleased to announce Tara...
SCOTTSDALE, ARIZONA, UNITED STATES, April 11, 2023/EINPresswire.com/ — Translational Drug Development (TD2), a precision oncology contract...
NEW YORK, Aug. 24, 2022 (GLOBE NEWSWIRE) — SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage...
NEW YORK, Aug. 09, 2022 (GLOBE NEWSWIRE) – SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a...